FrancophonIA/ELRC3.0 huggingface dataset:
English: Significantly more patients receiving 25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of ≤7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p<0.001).
Estonian: Oluliselt rohkem patsiente, kes said 25 mg alogliptiini pluss 30 mg pioglitasooni ja metformiini (33,2%), saavutas 52. nädalal HbA1c eesmärkväärtuse ≤ 7,0% võrreldes nendega, kes said 45 mg pioglitasooni ja metformiini (21,3%) (p < 0,001).
English: Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin in patients with GFR<60 mL/min.
Estonian: Patsientidel, kelle GFR on alla 60 ml/min, tuleb enne ravi alustamist metformiiniga üle vaadata riskitegurid, mis võivad suurendada laktatsidoosi riski (vt lõik 4.4).
English: At Week 52, the HbA1c reduction by 25 mg alogliptin plus metformin (-0.76%, Table 3) was similar to that produced by glipizide (mean dose = 5.2 mg) plus metformin hydrochloride therapy (mean dose = 1,824 mg, -0.73%).
Estonian: 52. nädalal oli HbA1c vähenemine 25 mg alogliptiini kasutamisel koos metformiiniga (-0,76%, tabel 3) sarnane glipisiidi (keskmine annus = 5,2 mg) kasutamisel metformiinvesnikkloriidiga saavutatud tulemusega (keskmine annus = 1824 mg, --0,73%).
English: For patients inadequately controlled on dual therapy with a maximal tolerated dose of metformin and pioglitazone, the dose of pioglitazone should be maintained, and Vipdomet administered concomitantly; alogliptin should be dosed at 12.5 mg twice daily (25 mg total daily dose) and metformin hydrochloride at a similar dose (either 850 mg or 1,000 mg twice daily) to that already being taken.
Estonian: Patsientidel, kes ei ole piisavalt kontrollitud maksimaalse talutava metformiini annuse ja pioglitasooni kaksikraviga, tuleb pioglitasooni annus säilitada ja Vipdometi manustada kaasuvana; alogliptiini tuleb manustada 12,5 mg kaks korda ööpäevas (25 mg ööpäevane annus) ja metformiinvesinikkloriidi samasuguses annuses (kas 850 mg või 1000 mg kaks korda ööpäevas), nagu juba võetakse.
English: Clinically meaningful reductions in HbA1c compared to control were also observed regardless of baseline background treatment.
Estonian: Samuti täheldati kliiniliselt olulist HbA1c vähenemist võrreldes kontrolliga sõltumata foonravist uuringu alguses.
English: Symptoms of lactic acidosis include: - vomiting - stomach ache (abdominal pain) - muscle cramps - a general feeling of not being well with severe tiredness
Estonian: Laktatsidoosi sümptomid on: - oksendamine - kõhuvalu - lihaskrambid
English: For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin, the dose of Vipdomet should provide alogliptin dosed at 12.5 mg twice daily (25 mg total daily dose) and a dose of metformin similar to the dose already being taken.
Estonian: Patsientidel, kes ei ole piisavalt kontrollitud kaksikraviga, mis koosneb insuliini ja maksimaalse talutava metformiini annusest, peab Vipdometi annus sisaldama alogliptiini 12,5 mg kaks korda ööpäevas (25 mg ööpäevane annus) ja metformiini samasuguses annuses, nagu juba võetakse.
English: Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score >9).
Estonian: Raske maksakahjustusega (Child-Pugh' skoor > 9) patsientidel ei ole alogliptiini uuritud.
English: Treatment-corrected change from baseline in HbA1c (%)†
Estonian: HbA1c raviga korrigeeritud muutus võrreldes algsega (%)† (1poolne CI)
English: Preclinical data for metformin reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.
Estonian: Farmakoloogilise ohutuse, korduvtoksilisuse, genotoksilisuse, kartsinogeensuse, reproduktsiooni- ja arengutoksilisuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: For the different dose regimens Vipdomet is available in strengths of 12.5 mg/850 mg and 12.5 mg/1,000 mg film-coated tablets.
Estonian: Erinevate annustamisskeemide järgimiseks on Vipdometi tabletid müügil tugevustega 12,5 / 850 mg, 12,5 / 1000 mg.
English: Very rare (may affect up to 1 in 10,000 people): - Lactic acidosis (a build-up of lactic acid in the blood) is a very serious side effect that may lead to coma.
Estonian: Väga harv (esineb kuni 1 inimesel 10 000-st) - Laktatsidoos (piimhappe kuhjumine veres).
English: What Vipdomet looks like and contents of the pack - Vipdomet 12.5 mg/850 mg film-coated tablets (tablets) are light yellow, oblong (approximately 21.0 mm long by 10.1 mm wide), biconvex, film-coated tablets with “12.5/850” debossed on one side and “322M” debossed on the other side.
Estonian: Kuidas Vipdomet välja näeb ja pakendi sisu - Vipdomet 12,5 mg/850 mg õhukese polümeerikattega tabletid (tabletid) on helekollased, piklikud (ligikaudu 21,0 mm pikad ja 10,1 mm laiad), kaksikkumerad, õhukese polümeerikattega tabletid, mille ühele küljele on sisse pressitud „12.5/850” ja teisele küljele „322M”.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 850 mg metformin hydrochloride.
Estonian: TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 12,5 mg alogliptiini (bensoaadina) ja 850 mg metformiinvesinikkloriidi.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 1,000 mg metformin hydrochloride.
Estonian: TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 12,5 mg alogliptiini (bensoaadina) ja 1000 mg metformiinvesinikkloriidi.
English: Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).
Estonian: Oluliselt rohkem patsiente, kes said 25 mg alogliptiini (49,2%), saavutas 26. nädalal HbA1c eesmärkväärtuse ≤ 7,0% võrreldes nendega, kes said platseebot (34,0%) (p = 0,004).
English: In humans, independently of its action on glycaemia, metformin has favourable effects on lipid metabolism.
Estonian: Inimestel on metformiinil selle toimest glükeemiale sõltumatu soodne toime lipiidide ainevahetusele.
English: Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (18.3%) at Week 26 (p<0.001).
Estonian: Oluliselt rohkem patsiente, kes said 25 mg alogliptiini (44,4%), saavutas 26. nädalal HbA1c eesmärkväärtuse ≤ 7,0% võrreldes nendega, kes said platseebot (18,3%) (p < 0,001).
English: More patients receiving 25 mg alogliptin (7.8%) achieved target HbA1c levels of ≤7.0% compared to those receiving placebo (0.8%) at Week 26.
Estonian: Oluliselt rohkem patsiente, kes said 25 mg alogliptiini (7,8%), saavutas 26. nädalal HbA1c eesmärkväärtuse ≤ 7,0% võrreldes nendega, kes said platseebot (0,8%).
English: You should take this medicine with food to reduce your chance of an upset stomach.
Estonian: Iivelduse tekkimise võimaluse vähendamiseks peate seda ravimit võtma koos toiduga.
English: Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1000 mg film-coated tablets alogliptin/metformin hydrochloride
Estonian: Vipdomet 12,5 mg / 850 mg õhukese polümeerikattega tabletid Vipdomet 12,5 mg / 1000 mg õhukese polümeerikattega tabletid alogliptiin/metformiinvesinikkloriid
English: Alogliptin 25 mg once daily with a sulphonylurea (n=197)
Estonian: Algoliptiin 25 mg üks kord ööpäevas koos sulfonüüluureaga (n = 197)
English: Liver function test abnormalities very rare hepatic dysfunction including hepatic failure not known
Estonian: Maksa ja sapiteede häired hepatiit väga harv maksafunktsiooni testide kõrvalekalded normist väga harv maksafunktsiooni häire, sh maksapuudulikkus teadmata
English: Each 12.5 mg/850 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 850 mg metformin hydrochloride.
Estonian: Üks 12,5 mg/850 mg õhukese polümeerikattega tablett sisaldab alogliptiinbensoaati koguses, mis vastab 12,5 mg alogliptiinile ja 850 mg metformiinvesinikkloriidile.
English: In addition, mean change from baseline in FPG at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p<0.001).
Estonian: Lisaks oli keskmine plasma paastuglükoosisisalduse muutus võrreldes algsega 52. nädalal 25 mg alogliptiini pluss 30 mg pioglitasooni ja metformiini puhul oluliselt suurem kui 45 mg pioglitasooni ja metformiini puhul (p < 0,001).
English: - in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation.
Estonian: - glükoositootmise vähendamine maksas glükoneogeneesi ja glükogenolüüsi inhibeerimise teel; - lihastes insuliinitundlikkuse suurendamine, mis parandab perifeerset glükoosi omastamist ja utiliseerimist; - glükoosi soolest imendumise aeglustamine.
English: Each 12.5 mg/1,000 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 1,000 mg metformin hydrochloride.
Estonian: Üks 12,5 mg/1000 mg õhukese polümeerikattega tablett sisaldab alogliptiinbensoaati koguses, mis vastab 12,5 mg alogliptiinile ja 1000 mg metformiinvesinikkloriidile.
English: In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively.
Estonian: Südame-veresoonkonnaga seotud ravitulemuste uuringus oli pankreatiidi esinemissagedus alogliptiini või platseeboga ravitud patsientidel vastavalt 3 või 2 juhtu 1000 patsiendi-aasta kohta.Turuletulekujärgselt on spontaanselt teatatud ägedast pankreatiidist kui kõrvaltoimest.
English: - Vipdomet 12.5 mg/1,000 mg film-coated tablets (tablets) are pale yellow, oblong (approximately 22.3 mm long by 10.7 mm wide), biconvex, film-coated tablets with “12.5/1000” debossed on one side and “322M” debossed on the other side.
Estonian: - Vipdomet 12,5 mg/1000 mg õhukese polümeerikattega tabletid (tabletid) on kahvatukollased, piklikud (ligikaudu 22,3 mm pikad ja 10,7 mm laiad), kaksikkumerad, õhukese polümeerikattega tabletid, mille ühele küljele on sisse pressitud „12.5/1000” ja teisele küljele „322M”.
English: Microcrystalline cellulose Povidone K30
Estonian: Mikrokristalliline tselluloos
English: The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean dose = 1,847 mg) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 2).
Estonian: 25 mg alogliptiini üks kord ööpäevas lisamine ravile metformiiniga (keskmine annus 1,847 mg) põhjustas 26. nädalal võrreldes platseebo lisamisega statistiliselt olulist algse HbA1c ja plasma paastuglükoosisisalduse vähenemist (tabel 2).
English: Alogliptin as add-on therapy to metformin with insulin The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to the addition of placebo (Table 2).
Estonian: Alogliptiin täiendava ravina lisaks metformiini ja insuliini kombinatsioonile 25 mg alogliptiini üks kord ööpäevas lisamine insuliinravile (keskmine annus 56,5 RÜ, koos metformiiniga või ilma selleta) põhjustas 26. nädalal statistiliselt olulist algse HbA1c ja FPG vähenemist võrreldes platseebo lisamisega (tabel 2).
English: Alogliptin as add-on therapy to metformin with a thiazolidinedione The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 2).
Estonian: Alogliptiin täiendava ravina lisaks tiasolidiindiooni ja metformiini kombinatsioonile 25 mg alogliptiini üks kord ööpäevas lisamine pioglitasoonravile (keskmine annus = 35,0 mg, koos metformiini või sulfonüüluureaga või ilma nendeta) põhjustas 26. nädalal statistiliselt olulise algse HbA1c ja plasma paastuglükoosisisalduse vähenemise võrreldes platseebo lisamisega (tabel 2).
English: NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1,000 mg film-coated tablets
Estonian: RAVIMPREPARAADI NIMETUS Vipdomet 12,5 mg/850 mg õhukese polümeerikattega tabletid Vipdomet 12,5 mg/1000 mg õhukese polümeerikattega tabletid
English: Placebo-corrected change from baseline in HbA1c (%)†
Estonian: Platseeboga korrigeeritud HbA1c muutus võrreldes algsega (%)† (2-poolne 95%
English: MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/026 196 (2x98) film-coated tablets (multipack)
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/13/843/026 196 (2x98) õhukese polümeerikattega tabletti (multipakend)
English: MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 2x98 film-coated tablets
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/13/843/025 2x98 õhukese polümeerikattega tabletti
English: More patients receiving 25 mg alogliptin and metformin (48.5%) achieved target HbA1c levels of ≤7.0% compared to those receiving glipizide and metformin (42.8%) (p=0.004).
Estonian: HbA1c taseme ≤ 7,0% saavutas rohkem patsientidest, kes kasutasid 25 mg alogliptiini koos metformiiniga (48,5%) võrreldes glipisiidi koos metformiiniga kasutanud patsientidega (42,8%) (p = 0,004).
English: MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/026 2x98 film-coated tablets
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/13/843/026 2x98 õhukese polümeerikattega tabletti
English: MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 196 (2x98) film-coated tablets (multipack)
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/13/843/025 196 (2x98) õhukese polümeerikattega tabletti (multipakend)
English: Crospovidone Type A Magnesium stearate
Estonian: Krospovidoon, A-tüüpi
English: In studies in vitro, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with disposition of the active substance in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2).
Estonian: In vitro uuringutes leiti, et alogliptiin ei ole toimeaine neerudes eritumisega seotud transporterite substraat ega inhibiitor.
English: - if you have -severely reduced kidney function - if you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactate acidosis (see “Risk of lactic acidosis” below) or ketoacidosis.
Estonian: Täiendavad sümptomid võivad olla üldine sügelus ja kuumatunne, eriti peanahal, suus, kõris, peopesadel ja taldadel (StevensJohnsoni sündroom); - kui teie neerufunktsioon on oluliselt langenud; - kui teil on kontrollimata diabeet, millega kaasneb nt raske hüperglükeemia (kõrge veresuhkru sisaldus veres), iiveldus, oksendamine, kõhulahtisus, kiire kehakaalu langus, laktatsidoos (vt lõik allpool „Laktatsidoosi risk“) või ketoatsidoos.
English: NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/1,000 mg tablets alogliptin/metformin hydrochloride
Estonian: RAVIMPREPARAADI NIMETUS Vipdomet 12,5 mg/1000 mg tabletid alogliptiin/metformiinvesinikkloriid
English: NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg tablets alogliptin/metformin hydrochloride
Estonian: RAVIMPREPARAADI NIMETUS Vipdomet 12,5 mg/850 mg tabletid alogliptiin/metformiinvesinikkloriid
English: Maximum daily dose is 3,000 mg Dose reduction may be considered in relation to declining renal function.
Estonian: Halveneva neerufunktsiooni korral võib kaaluda annuse vähendamist.
English: NAME OF THE MEDICINAL PRODUCT Vipdomet 12.5 mg/850 mg film-coated tablets alogliptin/metformin hydrochloride
Estonian: RAVIMPREPARAADI NIMETUS Vipdomet 12,5 mg/850 mg õhukese polümeerikattega tabletid alogliptiin/metformiinvesinikkloriid
English: - if you have or have had a disease of the pancreas.
Estonian: Vipdometiga; - kui teil on või on olnud kõhunäärmehaigus; - kui ravi ajal Vipdometiga tekivad maksakahjustusele viitavad sümptomid.
English: Nonfatal Myocardial Infarction
Estonian: Surmaga mittelõppenud müokardiinfarkt
English: Pale yellow, oblong (approximately 22.3 mm long by 10.7 mm wide), biconvex, film-coated tablets with “12.5/1000” debossed on one side and “322M” debossed on the other side.
Estonian: Vipdomet 12,5 mg/1000 mg õhukese polümeerikattega tabletid Kahvatukollased, piklikud (ligikaudu 22,3 mm pikad ja 10,7 mm laiad), kaksikkumerad, õhukese polümeerikattega tabletid, mille ühele küljele on sisse pressitud „12.5/1000” ja teisele küljele „322M”.
English: 2630 Taastrup
Estonian: Povidoon K30
English: Add-on combination therapy studies Alogliptin 25 mg once daily with metformin vs a sulphonylurea + metformin
Estonian: Täiendava kombinatsioonravi uuringud Alogliptiin 25 mg üks kord ööpäevas koos metformiiniga vs. sulfonüüluurea ja metformiin Muutus 52. nädalal (n = 382)
English: Light yellow, oblong (approximately 21.0 mm long by 10.1 mm wide), biconvex, film-coated tablets with “12.5/850” debossed on one side and “322M” debossed on the other side.
Estonian: Vipdomet 12,5 mg/850 mg õhukese polümeerikattega tabletid Helekollased, piklikud (ligikaudu 21,0 mm pikad ja 10,1 mm laiad), kaksikkumerad, õhukese polümeerikattega tabletid, mille ühele küljele on sisse pressitud „12.5/850” ja teisele küljele „322M”.
English: Zero days.
Estonian: 0 ööpäeva.
English: In some cases fever may occur for one day, and up to three days in exceptional circumstances.
Estonian: Mõnedel juhtudel võib ühe päeva jooksul esineda palavik, mis erandlikes tingimustes võib kesta kuni 3 päeva.
English: The swelling is expected to decrease within two days.
Estonian: Paistetus taandub eeldatavalt kahe päeva jooksul.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Equilis Te to Intervet International BV on 8 July 2005.
Estonian: Euroopa Komisjon andis Equilis Te müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Intervet International BV 08. juulil 2005.
English: All studies were performed with Equilis Prequenza Te (comment: double; mentioned in next paragraph).
Estonian: Kõik uuringud tehti Equilis Prequenza Tega (märkus: kahekordse toimega; kirjeldatakse järgmises lõigus).
English: The withdrawal period of the product is zero days.
Estonian: Toote keeluaeg on 0 ööpäeva.
English: The Committee recommended that Equilis Te should be given a marketing authorisation.
Estonian: Komitee soovitas anda Equilis Tele müügiloa.
English: The disease, which usually originates from contaminated wounds, is characterised by overall rigidity (stiffness) and convulsive spasms of the muscles.
Estonian: Tavaliselt saastunud haavadest lähtunud haigust iseloomustab üldine rigiidsus (jäikus) ja lihaste kramplikud kokkutõmbed.
English: Studies in pregnant mares were also performed.
Estonian: Uuringud tehti ka tiinetel märadel.
English: This summary was last updated in October 2008.
Estonian: Kokkuvõtte viimane uuendus: 10-2008.
English: Equilis Te is a vaccine for use in horses.
Estonian: Equilis Te on hobustel kasutatav vaktsiin.
English: Tetanus is an acute, often fatal disease caused by a neurotoxin produced by the bacterium Clostridium tetani.
Estonian: Teetanus on äge, sageli surmaga lõppev haigus, mille põhjustajaks on bakteri Clostridium tetani poolt toodetud neurotoksiin (närvimürk).
English: Horses belong to the most susceptible species to tetanus.
Estonian: Hobused kuuluvad teetanuse suhtes tundlikemate liikide hulka.
English: The first revaccination should be no later than 17 months after primary vaccination.
Estonian: Esimene kordusvaktsineerimine tuleb teha hiljemalt 17 kuud pärast esmast vaktsineerimist.
English: This helps to protect against tetanus.
Estonian: See aitab looma kaitsta teetanuse vastu.
English: Horses developed protection two weeks after primary vaccination.
Estonian: Hobustel tekkis kaitse kaks nädalat pärast esmast vaktsineerimist.
English: To retain protection against tetanus, horses need to be revaccinated.
Estonian: Kaitse säilitamiseks teetanuse vastu peab hobuseid korduvalt vaktsineerima.
English: It was concluded that the product is well tolerated by horses of different age.
Estonian: Järeldati, et eri vanuses hobused taluvad ravimit hästi.
English: Afterwards, a maximum interval of two years is recommended.
Estonian: Edaspidi on soovitatav korrata vaktsineerimist maksimaalselt kaheaastase intervalliga.
English: For ethical reasons no challenge (infection) experiment was performed against tetanus.
Estonian: Eetilistel põhjustel ei tehtud teetanuse infektsiooniga kokkupuute katset.
English: The effectiveness of Equilis Te has been studied in several trials under laboratory and field conditions.
Estonian: Equilis Te tõhusust uuriti mitmes uuringus nii laboritingimustes kui ka tegelikus kasutuskeskkonnas.
English: The main measure of effectiveness was the production of protective levels of antibodies against tetanus toxoid after vaccination.
Estonian: Efektiivsuse peamine näitaja oli vaktsineerimisjärgne teetanuse toksoidi vastaste antikehade kaitsva taseme teke.
English: Most of the studies were performed with Equilis Prequenza Te, a vaccine that protects against equine influenza as well as against tetanus.
Estonian: Enamik uuringuid viidi läbi Equilis Prequenza Tega, vaktsiiniga, mis kaitseb nii hobuste gripi kui ka teetanuse vastu.
English: What is Equilis Te?
Estonian: Mis on Equilis Te?
English: Why has Equilis Te been approved?
Estonian: Miks Equilis Te heaks kiideti?
English: Horses should receive a primary vaccination, consisting of two injections given four weeks apart.
Estonian: Hobustele tuleb teha esmane vaktsineerimine, mis koosneb kahest neljanädalase vahega tehtud süstist.
English: The vaccine also contains an ‘adjuvant' to stimulate a better immune response.
Estonian: Vaktsiin sisaldab tugevama immuunreaktsiooni stimuleerimiseks adjuvanti (toimet tugevdav aine).
English: It contains the toxoid (chemically inactivated toxin) from the tetanus bacterium.
Estonian: See sisaldab teetanustoksoidi (teetanuse bakteri keemiliselt inaktiveeritud toksiin).
English: Equilis Te is a vaccine containing purified tetanus toxoid.
Estonian: Equilis Te on teetanuse puhastatud toksoidi sisaldav vaktsiin.
English: What is the risk associated with Equilis Te?
Estonian: Mis riskid Equilis Tega kaasnevad?
English: Swelling (max. diameter 5 cm) may occur at the injection site, either as diffuse hard or soft swelling.
Estonian: Süstekohas võib tekkida kas difuusne kõva või pehme paistetus (maksimaalse diameetriga 5 cm).
English: The safety of Equilis Te was studied in several studies under laboratory and field conditions in a large number of horses, from 2 months of age.
Estonian: Equilis Te ohutust uuriti paljudel vähemalt 2 kuu vanustel hobustel mitmes uuringus nii laboritingimustes kui ka tegelikus kasutuskeskkonnas.
English: The toxoid is a toxin processed in order to remove its toxic effect, but retain its antigenic properties.
Estonian: Toksoid on toksiin, mida on töödeldud selle toksilise toime eemaldamiseks, kuid antigeensete (organismi kaitsereaktsiooni esile kutsuvate) omaduste säilitamiseks.
English: The duration of protection against tetanus was 17 months after primary vaccination and 24 months after the first revaccination.
Estonian: Esmase vaktsineerimise järgne kaitse kestis 17 kuud ja esimese kordusvaktsineerimise järgne kaitse 24 kuud.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against diseases.
Estonian: Vaktsiinid õpetavad immuunsüsteemi ennast haiguste eest kaitsma.
English: What benefit has Equilis Te shown during the studies?
Estonian: Milles seisneb uuringute põhjal Equilis Te kasulikkus?
English: How does Equilis Te work?
Estonian: Kuidas Equilis Te toimib?
English: Equilis Te is used to vaccinate horses from six months of age against tetanus to prevent mortality.
Estonian: Equilis Ted kasutatakse vähemalt 6 kuu vanuste hobuste vaktsineerimiseks teetanuse vastu suremuse ennetamiseks.